Osimertinib plus Chemotherapy in EGFR-Mutated NSCLC (FLAURA2) @NEJMgroup
Osimertinib plus Chemotherapy in EGFR-Mutated NSCLC (FLAURA2) @NEJMgroup
Uploaded July 2026 | Updated September 2026, 1 week ago
NEJM Editorial Fellow Katerina Lin, MD, outlines results of the FLAURA2 trial that analyzed osimertinib plus chemotherapy in EGFR-mutated advanced non–small-cell lung cancer.

Read the full trial results at NEJM.org.

#oncology #clinicaltrials #nejm
Osimertinib plus Chemotherapy in EGFR-Mutated NSCLC (FLAURA2)Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE)Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma (LITESPARK-022)NEJM Interview: Sara Gerke on a Utah pilot program involving an AI system that autonomously renew...NEJM Interview: Yaara Zisman-Ilani on navigating the uncertainty surrounding medication managemen...Ask the Expert: HFpEF Standard of CareMoney and MisdiagnosisNEJM This Week — June 25, 2026Images in Clinical Medicine: Cerebral Syphilitic GummaClinical Practice: SyncopeNEJM Clinician: The Troubling Rise of Medical Credit CardsJoseph Graves, PhD, on the Myth of Race and Genetics
NEJM Group |

Osimertinib plus Chemotherapy in EGFR-Mutated NSCLC (FLAURA2)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER